Predilife SA is a France-based company specialized in the development of predictive tests in the medical industry. The Company operates mainly in the field of oncology. Predilife offers MammoRisk, which is a predictive breast cancer test that combines medical imaging thanks to a proprietary software, DenSeeMammo, Big Data and statistics through a scoring tool and genetic profiles via a polygenic risk score (PRS). The image is analysed in order to extract the breast density and the first breast cancer risk factor. In addition, The technology used by MammoRisk makes it possible to evaluate from a database of individuals tracked over time, the risks of an individual to develop cancer compared to the fate of his/her closest neighbors through a database of a number of American and French women.